These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 38818815)

  • 21. Metabolic heterogeneity of human hepatocellular carcinoma: implications for personalized pharmacological treatment.
    Berndt N; Eckstein J; Heucke N; Wuensch T; Gajowski R; Stockmann M; Meierhofer D; Holzhütter HG
    FEBS J; 2021 Apr; 288(7):2332-2346. PubMed ID: 33030799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.
    Ding Z; Ericksen RE; Escande-Beillard N; Lee QY; Loh A; Denil S; Steckel M; Haegebarth A; Wai Ho TS; Chow P; Toh HC; Reversade B; Gruenewald S; Han W
    J Hepatol; 2020 Apr; 72(4):725-735. PubMed ID: 31726117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway.
    Zheng YL; Li L; Jia YX; Zhang BZ; Li JC; Zhu YH; Li MQ; He JZ; Zeng TT; Ban XJ; Yuan YF; Li Y; Guan XY
    Theranostics; 2019; 9(3):796-810. PubMed ID: 30809309
    [No Abstract]   [Full Text] [Related]  

  • 24. Targeting p300/CBP Attenuates Hepatocellular Carcinoma Progression through Epigenetic Regulation of Metabolism.
    Cai LY; Chen SJ; Xiao SH; Sun QJ; Ding CH; Zheng BN; Zhu XY; Liu SQ; Yang F; Yang YX; Zhou B; Luo C; Zhang X; Xie WF
    Cancer Res; 2021 Feb; 81(4):860-872. PubMed ID: 33361394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Metabolic Reprogramming in the Tumor Immune Microenvironment: Mechanisms and Opportunities for Immunotherapy in Hepatocellular Carcinoma.
    Hu N; Li H; Tao C; Xiao T; Rong W
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α.
    Yang N; Wang T; Li Q; Han F; Wang Z; Zhu R; Zhou J
    J Cell Physiol; 2021 May; 236(5):3863-3880. PubMed ID: 33305825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long noncoding RNA LINC01234 promotes hepatocellular carcinoma progression through orchestrating aspartate metabolic reprogramming.
    Chen M; Zhang C; Liu W; Du X; Liu X; Xing B
    Mol Ther; 2022 Jun; 30(6):2354-2369. PubMed ID: 35192933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1α-mediated Warburg effect.
    Chen Z; Zuo X; Zhang Y; Han G; Zhang L; Wu J; Wang X
    Cell Death Dis; 2018 May; 9(5):549. PubMed ID: 29748591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decoding the Roles of Long Noncoding RNAs in Hepatocellular Carcinoma.
    Wong LS; Wong CM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33808647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma.
    Ribback S; Che L; Pilo MG; Cigliano A; Latte G; Pes GM; Porcu A; Pascale RM; Li L; Qiao Y; Dombrowski F; Chen X; Calvisi DF
    Cell Cycle; 2018; 17(12):1496-1512. PubMed ID: 29965794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways.
    Li J; Huang Q; Long X; Zhang J; Huang X; Aa J; Yang H; Chen Z; Xing J
    J Hepatol; 2015 Dec; 63(6):1378-89. PubMed ID: 26282231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Research progress of non-coding RNA involved in glycolysis regulation of hepatocellular carcinoma].
    Hu XF; Zhang Q; Liang ML; Zhou QN; Zhao RQ; Gong ZK; Lin WZ
    Sheng Li Xue Bao; 2024 Apr; 76(2):319-328. PubMed ID: 38658380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid metabolism-related long noncoding RNA RP11-817I4.1 promotes fatty acid synthesis and tumor progression in hepatocellular carcinoma.
    Wang RY; Yang JL; Xu N; Xu J; Yang SH; Liang DM; Li JZ; Zhu H
    World J Gastroenterol; 2024 Feb; 30(8):919-942. PubMed ID: 38516243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer.
    Bao MH; Wong CC
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer-related microRNAs and their role as tumor suppressors and oncogenes in hepatocellular carcinoma.
    Gailhouste L; Ochiya T
    Histol Histopathol; 2013 Apr; 28(4):437-51. PubMed ID: 23224781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Lipid Metabolism in Liver Cancer.
    Alannan M; Fayyad-Kazan H; Trézéguet V; Merched A
    Biochemistry; 2020 Oct; 59(41):3951-3964. PubMed ID: 32930581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mito-Nuclear Communication in Hepatocellular Carcinoma Metabolic Rewiring.
    Mello T; Simeone I; Galli A
    Cells; 2019 May; 8(5):. PubMed ID: 31060333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dysregulated signaling hubs of liver lipid metabolism reveal hepatocellular carcinoma pathogenesis.
    Lee S; Mardinoglu A; Zhang C; Lee D; Nielsen J
    Nucleic Acids Res; 2016 Jul; 44(12):5529-39. PubMed ID: 27216817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma.
    Yang N; Li S; Li G; Zhang S; Tang X; Ni S; Jian X; Xu C; Zhu J; Lu M
    Oncotarget; 2017 Jan; 8(2):3683-3695. PubMed ID: 27713136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GATA5 inhibits hepatocellular carcinoma cells malignant behaviours by blocking expression of reprogramming genes.
    Feng H; Zhu M; Zhang R; Wang Q; Li W; Dong X; Chen Y; Lu Y; Liu K; Lin B; Guo J; Li M
    J Cell Mol Med; 2019 Apr; 23(4):2536-2548. PubMed ID: 30672133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.